#SFHS2609227VRegulation on Pricing of BAHA 7 Bone-Conducting Hearing Aids
AI-generated summary for informational purposes only. Not legal advice. See the original source for the authoritative text.
This regulation sets the maximum selling prices for BAHA 7 bone-conducting hearing aids in France. It establishes the prices that distributors can charge when selling directly to social insurance beneficiaries, as well as public retail prices for the products. The regulation includes specified prices for the years 2027 and 2028 as well, ensuring price stability and transparency in the market for these medical devices.
AI-generated summary. May contain errors. Refer to official sources for legal decisions.
Key Changes
- Maximum selling prices established for BAHA 7 hearing aids.
- Prices specified for the years 2027 and 2028.
- Prices set for both distributors and public retail.
Obligations
What this law requires
Distributors must not exceed the maximum selling price of €2,962.05 TTC for BAHA 7 bone-conducting hearing aid processors (code 2384447) when selling directly to social insurance beneficiaries, effective from the regulation's implementation date.
Distributors must charge a maximum cession price of €2,134.98 HT (excluding tax) for BAHA 7 processors when reselling directly to social insurance beneficiaries.
From January 2, 2027, distributors must reduce the maximum public retail price (PLV) for BAHA 7 processors to €2,939.19 TTC and the cession price to €2,113.31 HT.
From January 2, 2028, distributors must further reduce the maximum public retail price (PLV) for BAHA 7 processors to €2,927.76 TTC and the cession price to €2,102.48 HT.
Pricing must maintain compliance with the economic convention established between the health products economic committee and authorized signatories (COCHLEAR France, SDA, SYNAM, and SYNEA).